Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077865 · ClinicalTrials.gov registry record · Phase 1
Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects
A Phase 1 study, sponsored by TNF Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT05077865 is a Phase 1 study that has completed, run by TNF Pharmaceuticals. The registered enrollment target is 32 participants.
The verdict
NCT05077865, a Phase 1 study, has completed, sponsored by TNF Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Double-blind, placebo-controlled, single ascending and multiple dose study. Approximately 32 healthy adult male and female subjects will be given a single capsule of MYMD1 to determine its safety, tolerability, and pharmacokinetic properties. The study data will guide the establishment of an optimum therapeutic dose.
Interventions
- DRUG Placebo
- DRUG MYMD-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2021-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05077865
The ClinicalTrials.gov registry entry for NCT05077865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TNF Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05077865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05077865 about?
NCT05077865 is a clinical study titled "Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects". Double-blind, placebo-controlled, single ascending and multiple dose study. Approximately 32 healthy adult male and female subjects will be given a single capsule of MYMD1 to determine its safety, tolerability, and pharmacokinetic properties. The study data will guide the establishment of an optimum...
What is the current status of trial NCT05077865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2021-04-26. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT05077865?
The interventions under investigation include: Placebo (DRUG), MYMD-1 (DRUG).
Who is sponsoring clinical trial NCT05077865?
This trial is sponsored by TNF Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.